CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $20.31M, above the global median of $18.73M
- FinancialsAltman Z-Score 3.29: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.47%Below 5Y avg (2.33%)
Annual Rate
INR 2.00Paid annual
Payout Ratio
9.6%Sustainable
Last Ex-Dividend
Feb 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
39.21BINR408.65M · vs all stocks (USD)
Trailing P/E
21.01xRevenue (TTM)
26.78BINR279.03M · vs all stocks (USD)
Profit Margin
7.14%Beta
0.3140xvs all stocks
52-Week Change
-11.69%vs all stocks
Market Capitalization
39.21BINR408.65M · vs all stocks (USD)
Enterprise Value
44.54BINR464.11M · vs all stocks (USD)
Trailing P/E
21.01xForward P/E
15.77xPEG Ratio
-2.96xPrice to Sales (TTM)
1.50xPrice to Book (MRQ)
2.59xEnterprise to Revenue
1.66xEnterprise to EBITDA
13.26xGross Margin
39.16%Profit Margin
7.14%Operating Margin
11.46%Return on Assets (TTM)
6.92%Return on Equity (TTM)
12.58%Revenue (TTM)
26.78BINR279.03M · vs all stocks (USD)
Revenue per Share (TTM)
293.42INRUpdated Sep 29, 2026Quarterly Revenue Growth
19.00%Gross Profit (TTM)
10.05BINR104.69M · vs all stocks (USD)
EBITDA (TTM)
3.36BINR35.04M · vs all stocks (USD)
Net Income (TTM)
1.91BINR19.92M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.90%Operating Cash Flow (TTM)
2.54BINR26.42M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.95BINR20.31M · vs all stocks (USD)
Trailing Annual Dividend Rate
2.00INRUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.47%vs all stocks
5-Year Average Dividend Yield
2.33%vs all stocks
Payout Ratio
9.55%Minority Interest (Equity)
3.65MINRFY2026 · Mar 31, 2026Revenue
25.65BINRFY2026 · Mar 31, 2026Cost of Goods Sold
16.19BINRFY2026 · Mar 31, 2026Gross Profit
9.47BINRFY2026 · Mar 31, 2026Operating Income
2.42BINR25.24M · vs all stocks (USD)
Pre-tax Income
2.11BINRFY2026 · Mar 31, 2026Income Tax Expense
159.60MINRFY2026 · Mar 31, 2026Net Income
1.95BINRFY2026 · Mar 31, 2026EBIT
2.45BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
3.12BINRFY2026 · Mar 31, 2026Other Operating Expenses
5.08BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
337.10MINRFY2026 · Mar 31, 2026Minority Interests (P&L)
-203.00KINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
1.56BINRFY2026 · Mar 31, 2026Free Cash Flow
-174.50MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
72.70MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
2.11BINRFY2026 · Mar 31, 2026Other Non-cash Items
325.40MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-700.00MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-178.50MINRFY2026 · Mar 31, 2026Capital Expenditures
-1.73BINRFY2026 · Mar 31, 2026Net Acquisitions
0.00INRFY2026 · Mar 31, 2026Purchase of Investments
-15.50MINRFY2026 · Mar 31, 2026Sale of Investments
200.00KINRFY2026 · Mar 31, 2026Other Investing Activity
-100.00KINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-1.75BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
430.30MINRFY2026 · Mar 31, 2026Long-term Debt Payments
-567.80MINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-132.30MINRFY2026 · Mar 31, 2026Common Stock Repurchase
0.00INRFY2026 · Mar 31, 2026Common Dividends Paid
-181.70MINRFY2026 · Mar 31, 2026Other Financing Charges
100.00KINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-451.40MINRFY2026 · Mar 31, 2026Shares Outstanding
91.27MSharesUpdated Sep 29, 2026Float Shares
35.37MSharesUpdated Sep 29, 2026% Held by Insiders
59.56%vs all stocks
% Held by Institutions
11.09%vs all stocks
Total Cash (MRQ)
242.80MINR2.53M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.66INRUpdated Sep 29, 2026Total Debt (MRQ)
5.77BINR60.09M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3722xCurrent Ratio (MRQ)
1.59xBook Value per Share (MRQ)
169.79INRUpdated Sep 29, 2026Total Assets
28.15BINR293.38M · vs all stocks (USD)
Total Current Assets
14.68BINRFY2026 · Mar 31, 2026Total Liabilities
12.66BINRFY2026 · Mar 31, 2026Total Non-current Assets
13.47BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
3.44BINRFY2026 · Mar 31, 2026Total Current Liabilities
9.22BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
72.70MINRFY2026 · Mar 31, 2026Other Short-term Investments
170.10MINRFY2026 · Mar 31, 2026Accounts Receivable
8.30BINRFY2026 · Mar 31, 2026Inventory
4.91BINRFY2026 · Mar 31, 2026Accounts Payable
4.78BINRFY2026 · Mar 31, 2026Short-term Debt
3.19BINRFY2026 · Mar 31, 2026Other Current Liabilities
874.00MINRFY2026 · Mar 31, 2026Long-term Debt
2.58BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
-46.00KINRFY2026 · Mar 31, 2026Common Stock (Book)
912.70MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
15.49BINR161.44M · vs all stocks (USD)
52-Week Low
318.95INRUpdated Sep 29, 202652-Week High
534.00INRUpdated Sep 29, 202652-Week Change
-11.69%vs all stocks
Beta
0.3140xvs all stocks
50-Day MA
420.93INRUpdated Sep 29, 2026200-Day MA
386.80INRUpdated Sep 29, 2026Avg 10-Day Volume
162.42KSharesUpdated Sep 29, 2026Avg 30-Day Volume
150.47KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
20.94INRUpdated Sep 29, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.29: safe zoneNotable
Altman Z-Score: 3.29
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $20.31M, above the global median of $18.73MNotable
Levered free cash flow (USD): 20,312,342.254Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Hubei Goto Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule